This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Keurig Dr Pepper (KDP) Q2 Earnings Beat, Sales Lag Estimates
by Zacks Equity Research
Keurig Dr Pepper (KDP) posts mixed results in second-quarter 2019. Nevertheless, management reaffirms guidance for the current year.
Stock Futures Rebound Ahead of Trading
by Zacks Equity Research
Stock Futures Rebound Ahead of Trading
Index Futures Rebound as Yuan Worries Ease
by Zacks Equity Research
U.S. stocks futures inched higher ahead of trading on Thursday after China set the yuan's daily reference rate versus the dollar at a stronger than expected level.
Factors Likely to Shape Keurig Dr Pepper (KDP) Q2 Earnings
by Zacks Equity Research
Keurig Dr Pepper (KDP) is seeing strong retail market performance across most of its business along with merger-related synergies, which are likely to drive the company's second-quarter 2019 results.
Keurig Dr Pepper (KDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Keurig Dr Pepper (KDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coca-Cola (KO) to Report Q2 Earnings Tuesday: Should You Buy?
by Mitchell Moore
Coca-Cola Company (KO) stock was down 0.53% in trading Thursday. The stock currently sits less than a percent below its 52-week high.
Global Brands Bolster AB InBev's Sales, High Costs Remain Woe
by Zacks Equity Research
AB InBev (BUD) witnesses robust sales momentum on strength in global brands as well as global premiumization and revenue management plans. However, higher costs continue to mar the bottom line.
Near-Term Outlook for the Soft Drinks Industry Lacks Fizz
by Zacks Equity Research
Due efforts by soda companies to skew their portfolio toward health drinks and juices might aid a turnaround. However, the hazards of the CSD category remain.
PepsiCo (PEP) Q2 Earnings Beat, Segmental Results Drive Sales
by Zacks Equity Research
PepsiCo (PEP) beats earnings and sales estimates in second-quarter 2019. Results gain from strength in all of its businesses.
KO to Sell Its Own Energy Drinks, MNST's Objection Ruled Out
by Zacks Equity Research
Arbitrators provide clearance for the sale of Coca-Cola's (KO) energy drink brand. This resolves Coca-Cola's dispute with Monster Beverage regarding an agreement signed in 2015.
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Balanced Risk-Reward for Keurig Dr Pepper: Stock Up 18% YTD
by Zacks Equity Research
Keurig Dr Pepper (KDP) gains from long-term strategies and strong market share growth across portfolio. But soft CSD category, higher input costs and currency headwinds are hurting sales.
Top Stock Reports for Deere, Las Vegas Sands & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Deere (DE), Las Vegas Sands (LVS) and Vertex (VRTX).
What Makes Keurig Dr Pepper (KDP) a New Buy Stock
by Zacks Equity Research
Keurig Dr Pepper (KDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Keurig Dr Pepper (KDP) Up 0.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Keurig Dr Pepper (KDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Keurig Dr Pepper (KDP) Q1 Earnings Beat, Soft Sales Hurt Stock
by Zacks Equity Research
Keurig Dr Pepper (KDP) reports strong Q1 earnings, backed by higher operating income and reduced debt. However, effects of changes in the Allied Brands portfolio and a calendar shift mar the top line.
New Age Beverages (NBEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
New Age Beverages (NBEV) first-quarter 2019 results are likely to benefit from brand strength and the Morinda buyout.
Why Earnings Season Could Be Great for Keurig Dr Pepper (KDP)
by Zacks Equity Research
Keurig Dr Pepper (KDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Factors Likely to Shape Keurig Dr Pepper (KDP) Q1 Earnings
by Zacks Equity Research
Keurig Dr Pepper (KDP) witnesses softness at its Coffee Systems business, which might hurt its first-quarter 2019 results. However, it is gaining from the merged benefits and robust volume/mix.
Keurig Dr Pepper (KDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Keurig Dr Pepper (KDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Monster Beverage (MNST) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Monster Beverage's (MNST) robust trends in the energy drinks category might boost sales and earnings in first-quarter 2019. However, concerns regarding higher input and freight costs remain.
Will Lower Core Sales Hurt Newell's (NWL) Earnings in Q1?
by Zacks Equity Research
Newell (NWL) witnesses decline in core sales, which might hurt overall sales in first-quarter 2019.
Can AB InBev (BUD) Return to Earnings Beat Trend Amid Woes?
by Zacks Equity Research
AB InBev's (BUD) first-quarter 2019 earnings may continue to struggle due to soft trend of beer sales in the United States. However, its premiumization efforts and global brands' strength bode well.
Molson Coors (TAP) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Molson Coors (TAP) to gain from improved pricing, International strength and cost savings in first-quarter 2019. Soft North America volume, input cost inflation and currency headwinds may persist.
Factors Likely to Decide Avon's (AVP) Fate in Q1 Earnings
by Zacks Equity Research
Soft Representatives growth and currency headwind are likely to mar Avon's (AVP) Q1 results. However, the Open Up Avon strategy may bring some respite.